Rhythm Pharmaceuticals COO Pamela Cramer Sells 1520 Shares at $85.93 Each on 2025-07-29.
PorAinvest
martes, 29 de julio de 2025, 7:00 pm ET1 min de lectura
RYTM--
The transaction occurred amidst a period of market anticipation surrounding Rhythm Pharmaceuticals' upcoming earnings report, scheduled for release on August 5, 2025. Wall Street analysts expect the company to report a year-over-year decline in earnings, despite a significant increase in revenue [1].
The sale by Cramer, who holds a 10% ownership stake in the company, comes as analysts have recently revised their earnings estimates downward. The consensus estimate now projects a quarterly loss of $0.66 per share, representing a 20% year-over-year decrease. Revenue is expected to rise by 49.3% to $43.41 million [1].
The Earnings ESP (Expected Surprise Prediction) model, developed by Zacks Investment Research, indicates a negative ESP of -9.85% for Rhythm Pharmaceuticals. This suggests that analysts have become more bearish on the company's earnings prospects. The Zacks Rank of #3 for the stock makes it difficult to predict an earnings beat, although the company has a history of beating estimates in the past [1].
Investors should monitor the upcoming earnings report and other factors influencing the stock's performance. While the sale by Cramer may indicate a shift in sentiment, it is essential to consider the broader market conditions and the company's earnings trajectory.
References:
[1] https://www.nasdaq.com/articles/earnings-preview-rhythm-pharmaceuticals-inc-rytm-q2-earnings-expected-decline
[2] https://www.streetinsider.com/SEC+Filings/Form+4+RHYTHM+PHARMACEUTICALS%2C+For%3A+Jul+26+Filed+by%3A+Cramer+Pamela+J./25116049.html
Rhythm Pharmaceuticals, Inc. (RYTM) announced that Chief Human Resources Officer Pamela J. Cramer has sold 1,520 shares at $85.93 per share on July 29, 2025.
Rhythm Pharmaceuticals, Inc. (RYTM), a biopharmaceutical company, reported that its Chief Human Resources Officer, Pamela J. Cramer, sold 1,520 shares of the company's common stock on July 29, 2025. The sale was executed at $85.93 per share [2].The transaction occurred amidst a period of market anticipation surrounding Rhythm Pharmaceuticals' upcoming earnings report, scheduled for release on August 5, 2025. Wall Street analysts expect the company to report a year-over-year decline in earnings, despite a significant increase in revenue [1].
The sale by Cramer, who holds a 10% ownership stake in the company, comes as analysts have recently revised their earnings estimates downward. The consensus estimate now projects a quarterly loss of $0.66 per share, representing a 20% year-over-year decrease. Revenue is expected to rise by 49.3% to $43.41 million [1].
The Earnings ESP (Expected Surprise Prediction) model, developed by Zacks Investment Research, indicates a negative ESP of -9.85% for Rhythm Pharmaceuticals. This suggests that analysts have become more bearish on the company's earnings prospects. The Zacks Rank of #3 for the stock makes it difficult to predict an earnings beat, although the company has a history of beating estimates in the past [1].
Investors should monitor the upcoming earnings report and other factors influencing the stock's performance. While the sale by Cramer may indicate a shift in sentiment, it is essential to consider the broader market conditions and the company's earnings trajectory.
References:
[1] https://www.nasdaq.com/articles/earnings-preview-rhythm-pharmaceuticals-inc-rytm-q2-earnings-expected-decline
[2] https://www.streetinsider.com/SEC+Filings/Form+4+RHYTHM+PHARMACEUTICALS%2C+For%3A+Jul+26+Filed+by%3A+Cramer+Pamela+J./25116049.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios